Hepatic disposition of ximelagatran and Its metabolites in Pig; prediction of the impact of membrane transporters through a simple disposition model

Pharmaceutical Research

Volumn 27, Issue 4, 2010, Pages 597-607

  Sjögren, Erik ^a   Bredberg, Ulf ^b   Allard, Erik ^a   Arvidsson, Björn ^a,c   Bergquist, Jonas ^a   Andersson, Tommy B ^b,d   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c SWEDISH DEFENCE RESEARCH AGENCY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hepatic disposition; Hepatocytes; Kinetic modeling; Melagatran; Prodrug

Indexed keywords

BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; ERYTHROMYCIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KETOCONAZOLE; MELAGATRAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; QUINIDINE; QUININE; VERAPAMIL; XIMELAGATRAN; ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CENTRIFUGATION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; LIVER PARENCHYMA; MEMBRANE TRANSPORT; METHODOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUPERNATANT; SWINE; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; KINETICS; LIVER; METABOLISM;

ANIMALS; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; COMPUTER SIMULATION; HEPATOCYTES; KINETICS; LIVER; MODELS, BIOLOGICAL; PRODRUGS; SWINE;

EID: 77953146002     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0016-y     Document Type: Article

References (39)

1. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002; 360: 1441-1447
2. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral, direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003; 1: 41-47
3. ™. 2006. http://www.astrazeneca.com/pressrelease/5217.aspx.
4. Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, et al. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol. 1997; 51: 1024-1033
5. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001; 101: 171-181
6. Eriksson UG, Bredberg U, Hoffmann KT, Thuresson A, Gabrielsson M, Ericsson H, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003; 31: 294-305.
7. Sjodin E, Fritsch H, Eriksson U, Logren U, Nordgren A, Forsell P, et al. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos. 2008; 36: 1519-1528
8. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos. 2003; 31: 645-651
9. Andersson S, Hofmann Y, Nordling A, Li XQ, Nivelius S, Andersson TB, et al. Characterization and partial purification of the rat and human enzyme systems active in the reduction of Nhydroxymelagatran and benzamidoxime. Drug Metab Dispos. 2005; 33: 570-578
10. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450mediated drug-drug interactions. Clin Pharmacokinet. 2003; 42: 765-777
11. Eriksson UG, Dorani H, Karlsson J, Fritsch H, Hoffmann KJ, Olsson L, et al. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoproteinmediated excretion. Drug Metab Dispos. 2006; 34: 775-782
12. Sjogren E, Lennernas H, Andersson TB, Grasjo J, Bredberg U. The multiple depletion curves method, provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab Dispos. 2009; 37: 47-58.
13. Reese JA, Byard JL. Isolation and culture of adult hepatocytes from liver biopsies, in vitro. 1981; 17: 935-940
14. Schrickx J. ABC-transporters in the pig, Veterinary Pharmacology, Pharmacy and Toxicology. Utrecht: Universiteit Utrecht; 2006.
15. Arvidsson B, Allard E, Sjogren E, Lennernas H, Sjoberg PJ, Bergquist J. Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LC-MS/MS) of ximelagatran and its metabolites in a complex matrix. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877: 291-297
16. Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos. 2005; 33: 1304-1311
17. Bayliss MK, Bell JA, Jenner WN, Park GR, Wilson K. Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica. 1999; 29: 253-268
18. Reinoso RF, Telfer BA, Brennan BS, Rowland M. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab Dispos. 2001; 29: 453-459
19. Uhal BD, Roehrig KL. Effect of dietary state on hepatocyte size. Biosci Rep. 1982; 2: 1003-1007
20. Vom Dahl S, Hallbrucker C, Lang F, Gerok W, Haussinger D. Regulation of liver cell volume and proteolysis by glucagon and insulin. Biochem. J. 1991; 278(Pt 3): 771-777
21. Hallifax D, Houston JB. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos. 2006; 34: 1829-1836
22. Polsky-Fisher SL, Cao H, Lu P, Gibson CR. Effect of cytochromes P450 chemical inhibitors and monoclonal antibodies on human liver microsomal esterase activity. Drug Metab Dispos. 2006; 34: 1361-1366
23. Kenne K, Skanberg I, Glinghammar B, Berson A, Pessayre D, Flinois JP, et al. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol in vitro. 2008; 22: 730-746
24. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299: 620-628
25. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007; 35: 779-786
26. Lam JL, Okochi H, Huang Y, Benet LZ. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporterenzyme interplay. Drug Metab Dispos. 2006; 34: 1336-1344
27. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with, erythromycin in the human liver. Drug Metab Dispos. 2005; 33: 619-622
28. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, et al. Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000; 44: 1697-1700
29. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, et al. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002; 19: 147-153
30. Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998; 286: 354-361 (Pubitemid 28318011)
31. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000; 11: 207-214
32. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004; 311: 139-146 (Pubitemid 39287793)
33. Bow DA, Perry JL, Miller DS, Pritchard JB, Brouwer KL. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos. 2008; 36: 198-202.
34. Gratzl R, Lassacher R, Majcen A, Graf J. Redistribution of canalicular cell membrane enzyme in hepatocytes following their isolation and during early cell culture. Hepatology. 1997; 25: 502-504 (Pubitemid 27069082)
35. Gautam A, Ng OC, Strazzabosco M, Boyer JL. Quantitative assessment of canalicular bile formation in isolated hepatocyte couplets using microscopic optical planimetry. J Clin Invest. 1989; 83: 565-573 (Pubitemid 19061179)
36. Jones HM, Hallifax D, Houston JB. Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. Drug Metab Dispos. 2004; 32: 572-650
37. Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos. 2005; 33: 419-425 (Pubitemid 40279943)
38. Kilford PJ, Gertz M, Houston JB, Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos. 2008; 36: 1194-1197 (Pubitemid 351929330)
39. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, et al. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos. 2006; 34: 1600-1605